The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- FUTA wins 2026 Young Ocean Scholars University Research Competition, gets N10m prize money
- Anambra aims to eliminate mother to child HIV, hepatitis, syphilis
- FUTA teaching hospital: Success depends on stakeholder support
- Benue deputy gov assures transparent distribution of UNFPA kits
- ESDAN: Egg powder not the solution to egg glut
- Despite tight monetary policy, Nigeria’s broad money supply climbs to N129.21trn in May
- Nigerians keep N5.19trn outside banks despite cashless drive
- Santuscom’s fertilizer to improve soil, crops
